PubMed 28. Garnock-Jones KP, Keating GM, Scott LJ: Trastuzumab: a review of its use as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. Drugs 2010, 70:215–39.PubMedCrossRef 29. Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer
U, Bruzzi P: HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 2008, 100:14–20.PubMedCrossRef 30. Sobin LH, Wittekind C: UICC TNM Classification of Malignant Tumours. 6th edition. New York: Wiley-Liss; 2002. 31. Elston C, Ellis I: Pathological prognostic factors in selleck chemicals llc breast cancer. I. The value of histologic grade in breast cancer: experience from a large study with long-term follow-up. Histopatology 1991, 19:403–10.CrossRef 32. The World
Health Organization: Histological typing of breast tumors. Neoplasma 1983, 30:113–23. 33. Clarke SJ, Rivory LP: Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999, 36:99–114.PubMedCrossRef 34. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 1979, 277:665–67.PubMedCrossRef 35. Ganansia-Leymarie V, Bischoff P, Bergerat LY294002 cost JP, Holl V: Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anti-Canc Agents 2003, 3:291–306.CrossRef 36. Verweij JM, Clavel M, Chevalier B: Paclitaxel (Taxol™) and docetaxel (Taxotere™): Not simply two of a kind. Ann Oncol 1994, 5:495–505.PubMed 37. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995, 377:552–557.PubMedCrossRef 38. St Clair S, Manfredi JJ: The dual specificity phosphatase Cdc25C is a direct target for transcriptional repression by the tumor suppressor p53. Cell Cycle 2006, 5:709–713.PubMedCrossRef 39. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P: Mice lacking p21CIP1/WAF1 undergo normal
development, but are defective in G1 checkpoint Clomifene control. Cell 1995, 82:675–684.PubMedCrossRef 40. Norberg T, Lennerstrand J, Inganas M, Bergh J: Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer 1998, 79:376–383.PubMedCrossRef 41. Bertheau P, Espiè M, Turpin E, Lehmann J, Plassa LF, Varna M, Janin A, de Thè H: TP53 status and response to chemotherapy in breast cancer. Pathobiology 2008, 75:132–139.PubMedCrossRef 42. Berrieman HK, Lind MJ, Cawkwell L: Do β-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 2004, 5:158–64.PubMedCrossRef Competing interests The authors declare that they have no competing interests.